moxifloxacin has been researched along with benzyloxycarbonyl-phe-ala-fluormethylketone in 1 studies
| Studies (moxifloxacin) | Trials (moxifloxacin) | Recent Studies (post-2010) (moxifloxacin) | Studies (benzyloxycarbonyl-phe-ala-fluormethylketone) | Trials (benzyloxycarbonyl-phe-ala-fluormethylketone) | Recent Studies (post-2010) (benzyloxycarbonyl-phe-ala-fluormethylketone) |
|---|---|---|---|---|---|
| 3,157 | 552 | 1,690 | 5 | 0 | 5 |
| Protein | Taxonomy | moxifloxacin (IC50) | benzyloxycarbonyl-phe-ala-fluormethylketone (IC50) |
|---|---|---|---|
| Calpain-1 catalytic subunit | Homo sapiens (human) | 0.6 | |
| Cathepsin B | Homo sapiens (human) | 0.3 | |
| Calpain-2 catalytic subunit | Homo sapiens (human) | 0.6 | |
| Cysteine protease ATG4B | Homo sapiens (human) | 5.09 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, J; Gao, K; Huang, F; Tepe, JJ; Wang, R; Wei, GW | 1 |
1 other study(ies) available for moxifloxacin and benzyloxycarbonyl-phe-ala-fluormethylketone
| Article | Year |
|---|---|
Perspectives on SARS-CoV-2 Main Protease Inhibitors.
Topics: Antiviral Agents; Coronavirus 3C Proteases; Humans; Protease Inhibitors | 2021 |